{"id":"W3199693232","doi":"10.1177/17588359211034708","title":"New approaches to first-line treatment of advanced renal cell carcinoma","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Exelixis","keywords":"Axitinib; Medicine; Nivolumab; Pazopanib; Pembrolizumab; Cabozantinib; Sunitinib; Ipilimumab; Renal cell carcinoma; Oncology; Tyrosine-kinase inhibitor; Internal medicine; Avelumab; Kidney cancer; Lenvatinib; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003545188,0.0008862527,0.005907214,0.0004422201,0.00004222023,0.000005570181,0.000424648,0.0009181509,0.0009834861],"category_scores_gemma":[0.0001000427,0.000606917,0.0008550144,0.0008633081,0.0002381769,0.00005887815,0.0001416731,0.000630167,0.00006266985],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002208371,"about_ca_system_score_gemma":0.004213655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005119479,"about_ca_topic_score_gemma":0.0002112924,"domain_scores_codex":[0.9950089,0.0005102787,0.00173871,0.0010889,0.0008933981,0.0007598489],"domain_scores_gemma":[0.9961811,0.00131015,0.0005727444,0.0009533077,0.00005369657,0.0009289998],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003489182,0.001811767,0.00004509933,0.004792706,0.0002289514,0.001958812,0.0003309512,0.00003378631,0.000001400315,0.0002069067,0.0000343729,0.9902063],"study_design_scores_gemma":[0.004638056,0.01034142,0.00002969532,0.005178426,0.00180103,0.000592011,0.00007810591,0.00001155592,0.0001441507,0.0001265523,0.9766561,0.0004028323],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002010071,0.9894588,0.001081285,0.001126961,0.0004980275,0.002471046,0.00001885833,0.00003634287,0.005107675],"genre_scores_gemma":[0.0008689153,0.9870364,0.008703782,0.0002628952,0.0005951831,0.0006225984,0.0002621104,0.0001115954,0.001536529],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9898035,"threshold_uncertainty_score":0.9999297,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1690109399906946,"score_gpt":0.3992702987299874,"score_spread":0.2302593587392927,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}